Benzinga | Dec 9, 2021 09:45PM EST

Seagen Tukysa Maintains Survival Benefit, Delays Cancer Progression In The Brain In Breast Cancer Patients

Seagen Inc (NASDAQ:SGEN) has revealed new data from exploratory analyses from the HER2CLIMB trial of Tukysa (tucatinib) combined with trastuzumab & capecitabine in HER2-positive metastatic breast cancer with stable or active brain metastases.

* The data were featured at the 2021 San Antonio Breast Cancer Symposium.

* After a median follow-up of 29.6 months, the Tukysa regimen improved overall survival by 9.1 months compared to trastuzumab and capecitabine alone (21.6 months vs. 12.5 months).

* The benefit extended to patients with active or stable brain metastases.

* Tukysa treatment continued to show clinically meaningful benefit in progression-free survival in the central nervous system, representing a delay of cancer progression in the brain (9.9 months versus 4.2 months).

* The intracranial objective response rate and duration of objective response were consistent with previous analyses.

* Related Link: Seagen Bets On China's ADC In $2.6B Cancer Deal.

* Price Action: SGEN shares closed at $149.55 on Wednesday.